🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.660
0.00 (0.00%)
At close: Nov 20, 2026, 4:00 PM EST
2.650
-0.010 (-0.38%)
After-hours: Nov 20, 2026, 7:55 PM EST

Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of $28.91 million. The enterprise value is $19.92 million.

Market Cap28.91M
Enterprise Value 19.92M

Important Dates

The last earnings date was Monday, November 16, 2026, after market close.

Earnings Date Nov 16, 2026
Ex-Dividend Date n/a

Share Statistics

Aytu BioPharma has 10.87 million shares outstanding. The number of shares has increased by 107.64% in one year.

Current Share Class 10.87M
Shares Outstanding 10.87M
Shares Change (YoY) +107.64%
Shares Change (QoQ) +0.01%
Owned by Insiders (%) 5.14%
Owned by Institutions (%) 12.70%
Float 7.64M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.49
Forward PS 0.39
PB Ratio 0.92
P/TBV Ratio n/a
P/FCF Ratio 8.04
P/OCF Ratio 7.98
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.34
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 5.54

Financial Position

The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.52.

Current Ratio 1.07
Quick Ratio 0.86
Debt / Equity 0.52
Debt / EBITDA n/a
Debt / FCF 4.59
Interest Coverage -6.01

Financial Efficiency

Return on equity (ROE) is -73.44% and return on invested capital (ROIC) is -51.73%.

Return on Equity (ROE) -73.44%
Return on Assets (ROA) -17.93%
Return on Invested Capital (ROIC) -51.73%
Return on Capital Employed (ROCE) -23.43%
Weighted Average Cost of Capital (WACC) 6.57%
Revenue Per Employee $770,053
Profits Per Employee -$264,447
Employee Count76
Asset Turnover 0.52
Inventory Turnover 2.66

Taxes

In the past 12 months, Aytu BioPharma has paid $21,000 in taxes.

Income Tax 21,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +33.00% in the last 52 weeks. The beta is 0.22, so Aytu BioPharma's price volatility has been lower than the market average.

Beta (5Y) 0.22
52-Week Price Change +33.00%
50-Day Moving Average 2.05
200-Day Moving Average 2.28
Relative Strength Index (RSI) 79.51
Average Volume (20 Days) 375,678

Short Selling Information

The latest short interest is 301,698, so 2.78% of the outstanding shares have been sold short.

Short Interest 301,698
Short Previous Month 328,872
Short % of Shares Out 2.78%
Short % of Float 3.95%
Short Ratio (days to cover) 11.31

Income Statement

In the last 12 months, Aytu BioPharma had revenue of $58.52 million and -$20.10 million in losses. Loss per share was -$1.36.

Revenue58.52M
Gross Profit 37.07M
Operating Income -10.74M
Pretax Income -20.08M
Net Income -20.10M
EBITDA -6.49M
EBIT -10.74M
Loss Per Share -$1.36
Full Income Statement

Balance Sheet

The company has $25.49 million in cash and $16.51 million in debt, with a net cash position of $8.99 million or $0.83 per share.

Cash & Cash Equivalents 25.49M
Total Debt 16.51M
Net Cash 8.99M
Net Cash Per Share $0.83
Equity (Book Value) 31.56M
Book Value Per Share 2.90
Working Capital 3.84M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $3.62 million and capital expenditures -$29,000, giving a free cash flow of $3.60 million.

Operating Cash Flow 3.62M
Capital Expenditures -29,000
Depreciation & Amortization 4.25M
Net Borrowing -10.73M
Free Cash Flow 3.60M
FCF Per Share $0.33
Full Cash Flow Statement

Margins

Gross margin is 63.34%, with operating and profit margins of -18.35% and -34.34%.

Gross Margin 63.34%
Operating Margin -18.35%
Pretax Margin -34.31%
Profit Margin -34.34%
EBITDA Margin -11.10%
EBIT Margin -18.35%
FCF Margin 6.14%

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -107.64%
Shareholder Yield -107.64%
Earnings Yield -51.09%
FCF Yield 12.44%

Analyst Forecast

The average price target for Aytu BioPharma is $8.85, which is 232.71% higher than the current price. The consensus rating is "Buy".

Price Target $8.85
Price Target Difference 232.71%
Analyst Consensus Buy
Analyst Count 3
Revenue Growth Forecast (3Y) 26.39%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.

Last Split Date Jan 6, 2023
Split Type Reverse
Split Ratio 1:20

Scores

Altman Z-Score n/a
Piotroski F-Score 3